BioSpace News Archive

Summus Laser, the leading provider of high-powered laser therapy products, announces the launch of the Horizon Veterinary Laser System , the first Class IV therapy laser system designed specifically for the veterinary industry.

With the ongoing pandemic affecting in-person meetings and travel, two companies worked to bring surgeon training into the future using virtual reality (VR). Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, presented a training lab for surgeo

Summit Biolabs Announces Strategic Collaboration with Colorado Center for Personalized Medicine (CCPM) to Develop and Commercialize Saliva Liquid-biopsy Tests for COVID-19 and for Head & Neck Cancer [14-October-2020] AURORA, Colo. , Oct. 14, 2020 /PRNewswire/ -- Summit Biolabs, Inc., an early-stage molecular diagnostics company specializing in saliva-based testing

PulsePoint, a technology company using real-time data to accelerate health marketing, today announced the launch of PulsePoint Data Lab™, a collaborative incubator program designed to support early stage health data startups with opportunities to co-create commercial products and solutions.

RayzeBio, Inc. announced today a $45M Series A financing to advance the development of its broad pipeline of targeted radiopharmaceuticals. Co-lead investors venBio Partners and Versant Ventures were joined by Sam

As gene-based diagnostics are shortening the path to an accurate diagnosis, the risk of disparities in service and support have increased.

The collaboration for the discovery of novel selective tumor targets for Boehringer Ingelheim’s unique T-cell engager, cancer vaccine and oncolytic virus platforms, enabled by Oxford BioTherapeutics’ proprietary OGAP ® (Oxford Genome Anatomy Project) target discovery platform, is the latest in a series of collaborations that strengthens Boehringer Ingelheim’s position and leading assets in cancer immunology. INGELHEIM, Germany & OXFORD, En

Anika Chebrolu Takes Home Top Prize and Improving Lives Award at This Year’s 3M Young Scientist Challenge

- Trial met primary and all secondary endpoints for both 125- and 250-Unit doses with high statistical significance - - DaxibotulinumtoxinA for Injection was effective and generally well-tolerated in reducing the signs and symptoms for cervical dystonia, delivering up to a median duration of 24 weeks - - Results suggest DaxibotulinumtoxinA for Injection has the potential to reduce frequency of cervical dystonia treatments by up to 50% annually -

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Ryan Crowe as vice president, investor relations. In addition to managing day-to-day interactions with analysts and investors, Mr. Crowe will be responsible for developing and implementing a comprehensive and strategic global investor relations program. He will report to Frank Karbe, Myovant’s president an